or Try an Advanced Search...

    Technical Analysis for DVAX - Dynavax Technologies Corporation

    Grade Last Price % Change Price Change
    C 12.17 1.33% 0.16
    DVAX closed up 1.33 percent on Wednesday, November 20, 2024, on 58 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Down
    Historical DVAX trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    Calm After Storm Range Contraction 0.00%
    Oversold Stochastic Weakness 0.00%
    200 DMA Support Bullish 1.33%
    Calm After Storm Range Contraction 1.33%
    Stochastic Reached Oversold Weakness 1.33%
    Oversold Stochastic Weakness 1.33%
    Fell Below 20 DMA Bearish 4.11%
    MACD Bearish Signal Line Cross Bearish 4.11%
    New Downtrend Bearish 4.11%
    Older End-of-Day Signals for DVAX ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 20 DMA about 16 hours ago
    20 DMA Resistance about 17 hours ago
    Up 1% about 17 hours ago
    60 Minute Opening Range Breakout about 21 hours ago
    Rose Above Previous Day's High about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    DVAX Chart by TradingView
    Basic chart:

    Profile

    Dynavax Technologies Corporation Description

    Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company also develops DV1179, a Phase I bifunctional inhibitor of TLR7 and TLR9 for the treatment of autoimmune and inflammatory diseases; and AZD1419, a preclinical drug candidate for the treatment of asthma. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Inflammatory Diseases Hepatitis B Asthma Chronic Obstructive Pulmonary Disease Pulmonary Disease Autoimmune And Inflammatory Disease Novel Products Tlr7 Tlr9

    Is DVAX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 19 Dynavax Technologies Corporation (DVAX): This Small-Cap Stock Is Ready To Explode
    Nov 13 Dynavax Technologies: What The Stock Buyback Means, What It Doesn't
    Nov 11 Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
    Nov 11 Wall Street Analysts Predict an 88.32% Upside in Dynavax Technologies (DVAX): Here's What You Should Know
    Nov 11 Dynavax enters $100M accelerated share repurchase agreement
    Nov 11 Dynavax Announces $100 Million Accelerated Share Repurchase Program
    Nov 10 Dynavax Technologies Corporation Just Recorded A 9.1% EPS Beat: Here's What Analysts Are Forecasting Next
    Nov 9 Dynavax Technologies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
    Nov 8 Dynavax rises 11% on Q3 bottom line beat, 2024 positive net income expectation
    Nov 8 Dynavax Technologies Corp (DVAX) Q3 2024 Earnings Call Highlights: Record Hep B Sales and ...
    See more DVAX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 15.01
    52 Week Low 9.74
    Average Volume 2,352,469
    200-Day Moving Average 11.59
    50-Day Moving Average 11.45
    20-Day Moving Average 12.18
    10-Day Moving Average 12.72
    Average True Range 0.53
    RSI (14) 51.92
    ADX 28.08
    +DI 24.96
    -DI 26.04
    Chandelier Exit (Long, 3 ATRs) 12.31
    Chandelier Exit (Short, 3 ATRs) 12.25
    Upper Bollinger Bands 13.83
    Lower Bollinger Band 10.54
    Percent B (%b) 0.5
    BandWidth 27.04
    MACD Line 0.32
    MACD Signal Line 0.42
    MACD Histogram -0.0951
    Fundamentals Value
    Market Cap 1.57 Billion
    Num Shares 129 Million
    EPS 0.41
    Price-to-Earnings (P/E) Ratio 29.68
    Price-to-Sales 4.63
    Price-to-Book 2.76
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.90
    Resistance 3 (R3) 12.84 12.54 12.78
    Resistance 2 (R2) 12.54 12.35 12.57 12.74
    Resistance 1 (R1) 12.35 12.24 12.45 12.41 12.70
    Pivot Point 12.05 12.05 12.10 12.08 12.05
    Support 1 (S1) 11.87 11.87 11.96 11.93 11.64
    Support 2 (S2) 11.57 11.75 11.60 11.60
    Support 3 (S3) 11.38 11.57 11.56
    Support 4 (S4) 11.44